Search

Your search keyword '"HER2-positive early breast cancer"' showing total 3 results
Start Over Descriptor "HER2-positive early breast cancer" Publisher future medicine ltd
3 results on '"HER2-positive early breast cancer"'

1. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

Author

O'Sullivan, Ciara C, Ballman, Karla V, McCall, Linda, Kommalapati, Anuhya, Zemla, Tyler, Weiss, Anna, Mitchell, Melissa, Blinder, Victoria, Tung, Nadine M, Irvin, William J, Lee, Myounghee, Goetz, Matthew P, Symmans, William Fraser, Borges, Virginia F, Krop, Ian, Carey, Lisa A, and Partridge, Ann H

Subjects
BREAST tumor treatment, BREAST surgery, PYRIDINE, ADJUVANT chemotherapy, RESEARCH, HETEROCYCLIC compounds, CARCINOGENESIS, CANCER relapse, ANTINEOPLASTIC agents, PROGNOSIS, CELL receptors, BRAIN tumors, PLACEBOS, RANDOMIZED controlled trials, BREAST, BLIND experiment, RESEARCH funding, MASTECTOMY, COMBINED modality therapy, BREAST tumors
Abstract

This report describes the rationale, purpose and design of A011801 (CompassHER2 RD), an ongoing prospective, multicenter, Phase III randomized trial. Eligible patients in the United States (US) and Canada with high-risk (defined as ER-negative and/or node-positive) HER2-positive (HER2+) residual disease (RD) after a predefined course of neoadjuvant chemotherapy and HER2-directed treatment are randomized 1:1 to adjuvant T-DM1 and placebo, versus T-DM1 and tucatinib. Patients have also received adjuvant radiotherapy and/or endocrine therapy, if indicated per standard of care guidelines. The primary objective of the trial is to determine if the invasive disease-free survival (iDFS) with T-DM1 plus tucatinib is superior to iDFS with T-DM1 plus placebo; other outcomes of interest include overall survival (OS), breast cancer-free survival (BCFS), distant recurrence-free survival (DRFS), brain metastases-free survival (BMFS) and disease-free survival (DFS). Correlative biomarker, quality of life (QoL) and pharmacokinetic (PK) end points are also evaluated. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

2. Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients.

Author

Mustacchi, G, Puglisi, F, Molino, AM, Crivellari, D, Ghiotto, C, Ferro, A, Brunello, A, Saracchini, S, Turazza, M, Cretella, E, Iop, A, Malagoli, M, and Stefani, M

Abstract

Aim: This observational study investigates the use of adjuvant trastuzumab (AT) in HER2-positive breast cancer patients in a real-life setting, focusing on relapse and discontinuation rates. Patients & methods: Data on a group of HER2-positive patients collected from 13 oncology centers of northeast Italy were analyzed. Results: In total, 1245 patients were analyzed. 13.1% of patients were excluded from AT because of comorbidities, age, tumor stage, refusal or other reasons; 8.2% of patients who received AT interrupted the therapy, mainly for toxicity. Overall the relapse rate was 10.9% in the AT-treated population versus 22.6% in nontreated patients (follow-up: 37.4 and 62.1 months, respectively). Disease-free survival (DFS) was lower in AT-relapsed patients than in not-relapsed. Statistical analysis showed a correlation between DFS and estrogen receptor status in AT-treated patients. Conclusion: Relapse rates are lower in clinical setting compared to clinical trials. Overall, AT is effective in HER2-positive early-stage breast cancer patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

3. Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients

Author

Annamaria Molino, Diana Crivellari, A Iop, Antonella Brunello, Cristina Ghiotto, Micaela Stefani, Giorgio Mustacchi, Fabio Puglisi, Elisabetta Cretella, M. Turazza, M Malagoli, Silvana Saracchini, and A Ferro

Subjects
Cancer Research, medicine.medical_specialty, Receptor, ErbB-2, adjuvant trastuzumab, discontinuation rate, HER2-positive early breast cancer, luminal B-HER2-positive, real-life study, relapse rate, Oncology, medicine.medical_treatment, Population, Antineoplastic Agents, Breast Neoplasms, Breast cancer, Trastuzumab, Internal medicine, Humans, Medicine, skin and connective tissue diseases, education, Estrogen Receptor Status, Aged, Neoplasm Staging, Aged, 80 and over, education.field_of_study, business.industry, General Medicine, Middle Aged, medicine.disease, Survival Analysis, Surgery, Discontinuation, Clinical trial, Treatment Outcome, Italy, Chemotherapy, Adjuvant, Female, Observational study, business, Adjuvant, Follow-Up Studies, medicine.drug
Abstract

ABSTRACT Aim: This observational study investigates the use of adjuvant trastuzumab (AT) in HER2-positive breast cancer patients in a real-life setting, focusing on relapse and discontinuation rates. Patients & methods: Data on a group of HER2-positive patients collected from 13 oncology centers of northeast Italy were analyzed. Results: In total, 1245 patients were analyzed. 13.1% of patients were excluded from AT because of comorbidities, age, tumor stage, refusal or other reasons; 8.2% of patients who received AT interrupted the therapy, mainly for toxicity. Overall the relapse rate was 10.9% in the AT-treated population versus 22.6% in nontreated patients (follow-up: 37.4 and 62.1 months, respectively). Disease-free survival (DFS) was lower in AT-relapsed patients than in not-relapsed. Statistical analysis showed a correlation between DFS and estrogen receptor status in AT-treated patients. Conclusion: Relapse rates are lower in clinical setting compared to clinical trials. Overall, AT is effective in HER2-positive early-stage breast cancer patients.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results